RegisterLogin

Bevirimat

CAT: 0804-HY-N0842-01Size: 1 mgDry Ice: NoHazardous: No
CAT#:0804-HY-N0842-01Size:1 mg
Selected
PRICE
AVAILABILITY: InStock
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Product image 1
1 / 1
Description
Bevirimat (PA-457, MPC-4326, YK FH312) is an inhibitor of HIV-1 viral particle maturation.Bevirimat specifically inhibits the final rate-limiting step in Gag processing, preventing the release of the mature capsid protein (CA) from its precursor (CA-SP1), resulting in the production of immature non-infectious viral particles. Bevirimat can be used in HIV-1 infection studies[1][2][3][4].
CAS Number
[174022-42-5]
Product Name Alternative
PA-457; MPC-4326; YK FH312
UNSPSC
12352211
Target
Virus Protease
Type
Natural Products
Related Pathways
Anti-infection
Applications
COVID-19-anti-virus
Field of Research
Infection
Assay Protocol
https://www.medchemexpress.com/Bevirimat.html
Purity
99.82
Solubility
DMSO : ≥ 50 mg/mL
Smiles
OC([C@]1(CC[C@H]2C(C)=C)[C@@]2([H])[C@](CC[C@@]3([H])[C@]4(CC[C@]5([H])[C@@]3(CC[C@H](OC(CC(C)(C)C(O)=O)=O)C5(C)C)C)C)([H])[C@@]4(C)CC1)=O
Molecular Formula
C36H56O6
Molecular Weight
584.83
References & Citations
[1]Martin DE, et al. Bevirimat: a novel maturation inhibitor for the treatment of HIV-1 infection. Antivir Chem Chemother. 2008;19 (3) :107-13. |[2]Li F, et al. PA-457: a potent HIV inhibitor that disrupts core condensation by targeting a late step in Gag processing. Proc Natl Acad Sci U S A. 2003 Nov 11;100 (23) :13555-60. |[3]Blair WS, et al. New small-molecule inhibitor class targeting human immunodeficiency virus type 1 virion maturation. Antimicrob Agents Chemother. 2009 Dec;53 (12) :5080-7.|[4]Callies O, et al. Isolation, Structural Modification, and HIV Inhibition of Pentacyclic Lupane-Type Triterpenoids from Cassine xylocarpa and Maytenus cuzcoina. J Nat Prod. 2015 May 22;78 (5) :1045-55. |[5]Qian K, et al. Anti-AIDS agents 81. Design, synthesis, and structure-activity relationship study of betulinic acid and moronic acid derivatives as potent HIV maturation inhibitors. J Med Chem. 2010 Apr 22;53 (8) :3133-41. |[6]Zhao Y, et al. Design, synthesis, and structure activity relationship analysis of new betulinic acid derivatives as potent HIV inhibitors. Eur J Med Chem. 2021 Apr 5;215:113287.|[7]Qian K, et al. Anti-AIDS agents 90. novel C-28 modified bevirimat analogues as potent HIV maturation inhibitors. J Med Chem. 2012 Sep 27;55 (18) :8128-36.|[8]Stoddart CA, et al. Potent activity of the HIV-1 maturation inhibitor bevirimat in SCID-hu Thy/Liv mice. PLoS One. 2007 Nov 28;2 (11) :e1251.|[9]Zhao L, et al. Pre-clinical pharmacological profile of QF-036, a potent HIV-1 maturation inhibitor. Basic Clin Pharmacol Toxicol. 2021 Feb;128 (2) :275-285.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Natural Products
Clinical Information
Phase 2

Related Products

CatalogName

Alternative Products

CatalogName
MBS3610641-01Bevirimat
A14194-5Bevirimat 5mg
A14194-25Bevirimat 25mg
A14194-100Bevirimat 100mg
TYD-03550-01Bevirimat-CoA
A14194-1Bevirimat 1mg
A14194-10Bevirimat 10mg
A14194-50Bevirimat 50mg
MBS132472-01Bevirimat, PA-457
A14194-10mM-DBevirimat 10mM * 1mL in DMSO

Popular Products